Active substance
Haloperidol
- SFDA 12
- US FDA 127
- Health Canada 9
- US price lines 15
- NHS prices 10
- WHO EML 3
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| HALDOL 2MG-ML DROPS | 2 mg/ml | Oral drops · Oral use | 1 Bottle | SAR 11.45 | NCE · Prescription | JANSSEN PHARMACEUTICA N.V | Valid |
| HALDOL 5MG TABLET | 5 mg | Tablet · Oral use | 25 Blister | SAR 19.75 | Generic · Prescription | JANSSEN-CILAG | Valid |
| HALDOL 5MG-ML AMP | 5 mg/ml | Solution for injection · Parenteral use | 5 Ampoule | SAR 23.15 | NCE · Prescription | JANSSEN PHARMACEUTICA N.V | Valid |
| HALDOL DECANOAS INJ 100MG-ML | 100 mg/ml | Solution for injection · Intramuscular use | 1 Ampoule | SAR 41.35 | NCE · Prescription | JANSSEN PHARMACEUTICA N.V | Valid |
| HALDOL DECANOAS INJ 50MG | 50 mg/ml | Solution for injection · Intramuscular use | 1 Ampoule | SAR 21.85 | NCE · Prescription | JANSSEN PHARMACEUTICA N.V | Valid |
| SERENACE | 10 mg | Tablet · Oral use | 50 Blister | SAR 57.35 | NCE · Prescription | G.D.SEARLE | Withdrawn by MAH · Not Marketed |
| SERENACE | 1.5 mg | Tablet · Oral use | 50 Blister | SAR 16.45 | NCE · Prescription | G.D.SEARLE | Withdrawn by MAH · Not Marketed |
| SERENACE | 5 mg | Tablet · Oral use | 50 Blister | SAR 43.00 | NCE · Prescription | G.D.SEARLE | Withdrawn by MAH · Not Marketed |
| SYLADOR 0.5MG TAB | 0.5 mg | Tablet · Oral use | 60 Blister | SAR 14.05 | Generic · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| SYLADOR INJ 5MG-ML | 5 mg/ml | Solution · Parenteral use | 5 Ampoule | SAR 15.50 | Generic · Prescription | ALPHARMA APS | Invalid · Not Marketed |
| SYLADOR TAB 2 MG. | 2 mg | Tablet · Oral use | 60 Blister | SAR 23.80 | Generic · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
| SYLADOR TAB. 5 MG. | 5 mg | Tablet · Oral use | 60 Blister | SAR 56.70 | Generic · Prescription | ALPHARMA APS | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE MANIA; ALZHEIMER / DEMENTIA; ANESTHESIA; ANXIETY DISORDERS; ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD); AUTISM SPECTRUM DISORDER; HUNTINGTON'S DISEASE; POSTOPERATIVE NAUSEA AND VOMITING
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| HALOPERIDOL | 2MG; 1MG; 5MG; 0.5MG | tablet · oral | MYLAN | Prescription | 10 Jun 1986 |
| HALOPERIDOL | 0.5MG | tablet · oral | SANDOZ | Prescription | 17 Nov 1986 |
| HALOPERIDOL | 1MG | tablet · oral | SANDOZ | Prescription | 17 Nov 1986 |
| HALOPERIDOL | 5MG; 0.5MG; 1MG | tablet · oral | CHARTWELL RX | Prescription | 17 Nov 1986 |
| HALOPERIDOL | 2MG; 5MG; 10MG; 0.5MG; 1MG; 20MG | tablet · oral | AIPING PHARM INC | Prescription | 17 Feb 1987 |
| HALOPERIDOL | 10MG; 0.5MG; 1MG; 2MG; 5MG; 20MG | tablet · oral | SCIEGEN PHARMS | Prescription | 7 Jan 1988 |
| HALOPERIDOL | 10MG | tablet · oral | CHARTWELL RX | Prescription | 11 Mar 1988 |
| HALOPERIDOL | 20MG | tablet · oral | CHARTWELL RX | Prescription | 11 Mar 1988 |
| HALOPERIDOL | EQ 2MG BASE/ML | concentrate · oral | PHARM ASSOC | Prescription | 26 Feb 1993 |
| HALOPERIDOL | EQ 2MG BASE/ML | concentrate · oral | LANNETT CO INC | Prescription | 28 Sep 1993 |
| HALOPERIDOL DECANOATE | EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 19 Dec 1997 |
| HALOPERIDOL DECANOATE | EQ 100MG BASE/ML | injectable · injection | HIKMA PHARMS | Prescription | 28 Sep 1998 |
| HALOPERIDOL DECANOATE | EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | MYLAN LABS LTD | Prescription | 28 Feb 2000 |
| HALOPERIDOL | EQ 5MG BASE/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 9 Mar 2001 |
| HALOPERIDOL | EQ 5MG BASE/ML | injectable · injection | HIKMA PHARMS | Prescription | 18 Jun 2001 |
| HALOPERIDOL | 0.5MG; 1MG; 5MG; 10MG; 20MG; 2MG | tablet · oral | ZYDUS PHARMS USA | Prescription | 29 Nov 2007 |
| HALOPERIDOL | EQ 5MG BASE/ML | injectable · injection | MYLAN LABS LTD | Prescription | 14 Sep 2009 |
| HALOPERIDOL | EQ 5MG BASE/ML | injectable · injection | SAGENT PHARMS | Prescription | 2 Sep 2011 |
| HALOPERIDOL | EQ 5MG BASE/ML | injectable · injection | SAGENT PHARMS | Prescription | 2 Sep 2011 |
| HALOPERIDOL DECANOATE | EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | GLAND | Prescription | 12 May 2017 |
| HALOPERIDOL DECANOATE | EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | SOMERSET THERAPS LLC | Prescription | 3 Jul 2018 |
| HALOPERIDOL DECANOATE | EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | ZYDUS PHARMS | Prescription | 22 Oct 2019 |
| HALOPERIDOL | 0.5MG; 1MG; 2MG; 5MG; 10MG; 20MG | tablet · oral | APPCO | Prescription | 8 Jan 2020 |
| HALOPERIDOL DECANOATE | EQ 50MG BASE/ML; EQ 100MG BASE/ML | injectable · injection | MEITHEAL | Prescription | 26 Jul 2021 |
| HALOPERIDOL | 0.5MG; 1MG; 2MG; 5MG; 10MG; 20MG | tablet · oral | MSN | Prescription | 18 Nov 2022 |
102 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| HALOPERIDOL INJ 5MG/ML USP | 00808652 | 5 MG / ML | LIQUID · INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| HALOPERIDOL INJECTION | 02366010 | 5 MG / ML | SOLUTION · INTRAMUSCULAR | JUNO PHARMA CANADA INC. |
| HALOPERIDOL INJECTION, USP | 02406411 | 5 MG / ML | SOLUTION · INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
| HALOPERIDOL LA | 02130300 | 100 MG / ML | LIQUID · INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| TEVA-HALOPERIDOL | 00363650 | 5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-HALOPERIDOL | 00363669 | 2 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-HALOPERIDOL | 00363677 | 1 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-HALOPERIDOL | 00363685 | 0.5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-HALOPERIDOL | 00713449 | 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | HALOPERIDOL 0.5 MG TABLET | $0.08568 | per EA | 30 Sep 2026 |
| US NADAC | HALOPERIDOL 1 MG TABLET | $0.11953 | per EA | 30 Sep 2026 |
| US NADAC | HALOPERIDOL 10 MG TABLET | $0.14643 | per EA | 30 Sep 2026 |
| US NADAC | HALOPERIDOL 2 MG TABLET | $0.16576 | per EA | 30 Sep 2026 |
| US NADAC | HALOPERIDOL 20 MG TABLET | $0.37115 | per EA | 30 Sep 2026 |
| US NADAC | HALOPERIDOL 5 MG TABLET | $0.18065 | per EA | 30 Sep 2026 |
| US NADAC | HALOPERIDOL DEC 100 MG/ML AMP | $33.92227 | per ML | 23 Sep 2026 |
| US NADAC | HALOPERIDOL DEC 100 MG/ML VIAL | $16.1395 | per ML | 7 Oct 2026 |
| US NADAC | HALOPERIDOL DEC 100 MG/ML VIAL | $7.5241 | per ML | 23 Sep 2026 |
| US NADAC | HALOPERIDOL DEC 100 MG/ML VIAL | $15.59807 | per ML | 23 Sep 2026 |
| US NADAC | HALOPERIDOL DEC 50 MG/ML AMPUL | $20.75247 | per ML | 23 Sep 2026 |
| US NADAC | HALOPERIDOL DEC 50 MG/ML VIAL | $6.57233 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Haloperidol 1.5mg tablets | £4.65 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol 10mg tablets | £15.64 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol 10mg/5ml oral solution sugar free | £4.45 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol 200micrograms/ml oral solution sugar free | £185.00 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol 500microgram tablets | £225.28 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol 5mg tablets | £4.55 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol 5mg/1ml solution for injection ampoules | £35.83 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol 5mg/5ml oral solution sugar free | £25.10 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol decanoate 100mg/1ml solution for injection ampoules | £25.26 | 5 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Haloperidol decanoate 50mg/1ml solution for injection ampoules | £19.06 | 5 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 2.3. Medicines for other common symptoms in palliative care · core
Palliative care
Oral > Liquid: 2 mg per mL | Oral > Solid: 0.5 mg; 2 mg; 5 mg | Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule - 24.1. Medicines for psychotic disorders · core (EML); complementary (EMLc)
Schizophrenia or other primary psychotic disorders
Parenteral > General injections > IM: 5 mg per mL in ampoule | Oral > Solid: 2 mg; 5 mg - 24.1. Medicines for psychotic disorders · core
Therapeutic equivalent to fluphenazine for Schizophrenia or other primary psychotic disorders
Safety signals and safety-related labeling changes
- US FDA 30 Oct 2025 HALDOL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - MHRA 10 Dec 2021 Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium
We remind healthcare professionals that elderly patients are at an increased risk of adverse neurological and cardiac effects when being treated with haloperidol for delirium. The lowest possible dose of haloperidol should be used for the shortest possible time, and cardiac and extrapyramidal adverse effects should be closely monitored. - US FDA 17 Nov 2020 HALDOL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.